Cargando…
Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study
Introduction: Novel therapies are needed for the treatment of motion sickness given the inadequate relief and bothersome and dangerous adverse effects of currently approved therapies. Neurokinin-1 (NK1) receptor antagonists have the potential to be effective in improving the symptoms of motion sickn...
Autores principales: | Polymeropoulos, Vasilios M., Czeisler, Mark É., Gibson, Mary M., Anderson, Austin A., Miglo, Jane, Wang, Jingyuan, Xiao, Changfu, Polymeropoulos, Christos M., Birznieks, Gunther, Polymeropoulos, Mihael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550735/ https://www.ncbi.nlm.nih.gov/pubmed/33117260 http://dx.doi.org/10.3389/fneur.2020.563373 |
Ejemplares similares
-
Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial
por: Polymeropoulos, Christos M., et al.
Publicado: (2022) -
Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness
por: Czeisler, Mark É., et al.
Publicado: (2023) -
Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Polymeropoulos, Christos M., et al.
Publicado: (2020) -
Elevated plasma levels of CXCL16 in severe COVID-19 patients
por: Smieszek, Sandra P., et al.
Publicado: (2022) -
Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility
por: Smieszek, Sandra P., et al.
Publicado: (2021)